From DCAT Value Chain Insights (VCI)
Senior leadership from DG Health and Consumers (European Commission), the European Medicines Agency (EMA) and the FDA discussed a number of key initiatives at a bilateral meeting which took place in London from March 31 to April 1, 2014, reported EMA. These meetings take place approximately every 18 months. They provide an opportunity to review the broad strategic areas of collaboration for the oversight of safety, efficacy and quality of medicinal products, help to shape and orientate the scope of the routine information and work-sharing interactions between the two agencies, which now take place on a daily basis (80-90 per month).
This meeting provided an opportunity for the new leadership team at the EMA to meet their counterparts in FDA, as well as a chance to explore the possible impacts of changes in their respective organizations on a number of bilateral projects.
Participants at the meeting discussed a broad range of issues, including:
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription